Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-Term Safety of JNS001 (Concerta) in Adults with ADHD
NCT01357993Phase 3Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- May 2011
- Primary completion
- Mar 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of methylphenidate-OROS in attention deficit hyperactivity disorder (ADHD), sponsored by Janssen Pharmaceutical. Started May 2011; status: completed.
02
Drugs
methylphenidate-OROS
03
Conditions
attention deficit hyperactivity disorder (ADHD)
Beyond the preview
Go deeper on NCT01357993.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01357993.